Microbiotica: Wellcome Spin-Out Exploits Unique Microbe Collection

The first of Microbiotica Ltd.’s unique bacterial mixes will reach the clinic within the next two years, for a so-far undeclared indication, says company co-founder and CEO Mike Romanos. “We have a bacterial mix that is curative in animal models, so we should move into preclinical development within the coming year,” he adds.

Microbiotica Ltd is a microbiome-focused company that has just been spun out from the world-renowned Wellcome Trust Sanger Institute in Cambridge, the UK. It is concentrating on diseases where it...